Merck Announces Initial Results for KEYTRUDA with Novel Immunotherapy Combinations from Three Investigational Studies Presented at the Society for Melanoma Research International Congress
November 21, 2015 at 20:55 PM EST
Merck (NYSE: MRK) today announced findings from three studies investigating the use of KEYTRUDA® ...
